La Jolla Pharmaceuticals (NASDAQ: LJPC): Next Investment Idea With Upcoming Catalyst

LJPC

La Jolla Pharmaceuticals (LJPC) , a San Diego based emerging pharmaceuticals/biotechnology company is developing LJPC-501, a proprietary formulation of Angiotensin II (AT-II), a naturally occurring regulator of blood pressure.

(La Jolla Pharmaceuticals, common stock price chart)

L...

La Jolla Pharmaceuticals (LJPC) , a San Diego based emerging pharmaceuticals/biotechnology company is developing LJPC-501, a proprietary formulation of Angiotensin II (AT-II), a naturally occurring regulator of blood pressure.

(La Jolla Pharmaceuticals, common stock price chart)

L...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics